L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

So before I hand over to Paul ... But more importantly, I remember being here last year after we just changed our guidance and renewed our vows with science, that there was some raised eyebrows.

This includes medicated creams and pills, dupilumab (Dupixent ... the skin becomes inflamed and may itch more than before. While eczema’s cause is not known, it may stem from both environmental ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two ... are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before using DUPIXENT ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab ... But three years after buying Ziarco for an undisclosed sum, Novartis said the phase 2 drug ...

The median age was 15.8 years (IQR 9.3–19.5 years) and all patients had already failed conventional therapy Indeed, before dupilumab initiation, the median peak esophageal eosinophil count at biopsies ...

Most recently he was chief executive and co-founder of XenImmune Therapeutics, a start-up aiming to treat cancer by marking tumour cells as foreign to the immune system – and before that was CEO ...

The child had previously been treated with local injections of corticosteroids and developed total hair loss and AD after discontinuing corticosteroid ... antibodies targeting the type 2 inflammatory ...